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ABSTRACT 
 
 
  
 The goal of this project was to research the controversial topic of transgenic animals, and 
to look at both pros and cons of this ever-broadening technology.  The goal was accomplished by 
describing the process by which these animals are created, the ways in which they have been 
used, and the ways in which they can be beneficial to the society.  The ethical and moral 
implications of existing transgenic technologies, as well as the legal issues of patenting and 
owning life and genomes are discussed, presenting both sides of the arguments. Transgenic 
technology has a massive potential to benefit society, so long as the effect on the animals is 
minimal. 
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PROJECT OBJECTIVES 
 
 
 The goal of this project was to examine the topic of transgenic animals, and to discuss the 
effect of this controversial new technology on society.  First, the technology was investigated, by 
examining how transgenic animals are created and screened, and how they are used.  Then their 
effects on society are examined by an investigation of their ethics and legalities.  Examples of 
ethically justified and non-justified experiments are presented, and the laws governing the 
creation and use of transgenic animals are analyzed.  Finally, the authors make a conclusion 
based on their research. 
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Chapter 1:  Transgenic Technology 
 
Gregory Richmond 
 
 A transgenic animal has had its genome intentionally altered to allow that animal to better 
serve man.  Such animals include disease models to aid our understanding of diseases, 
transpharmers to produce pharmaceuticals in milk, xenotransplanters to produce organs for 
transplant, food sources, and scientific models to aid our understanding of biology.  Such 
amazing technological feats are performed through the use of recombinant DNA technology 
(rDNA), which involves splicing and cutting DNA (including between species) for the purpose 
of inserting or removing pieces from an animal‟s genome.  For this technology to be successful 
the inserted foreign gene must be successfully incorporated into the DNA of the host and be 
expressed correctly to give the animal its new trait.  The purpose of this chapter is to describe the 
way such animals are created, as a background for subsequent discussions on their their effects 
on society. 
 
Microinjection of DNA Into a Pronucleus 
 
 Transgenic animals are created through two main methods:  1) microinjection into the 
male pronucleus of a newly fertilized egg, or 2) microinjection, transfection, or viral infection of 
embryonic stem (ES) cells (“Transgenic Animals”, 2003).  The most common way of developing 
a transgenic animal is through microinjection of a gene into a male pronucleus.  A male 
pronucleus is the nucleus of the sperm inside a newly fertilized egg after they have have 
fertilized but before the two nuclei fuse.  The male pronucleus is used because it is slightly larger 
than the female pronucleus.  The transgene injection is performed by holding the fertilized egg in 
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place by a pipette with a small amount of suction, while another micropipette injects over 200 
copies of the desired gene into the pronucleus (Figure-1).   
 
 
 
 
 
 
 
Figure 1:  Photograph of Microinjection into the Male Pronucleus.  
The photo shows a large pipette (left side) holding the fertilized egg in 
place with gentle suction.  The micropipette for injecting DNA is shown 
on the right.  The male pronucleus is the sphere at the center left (Oregon 
Health, 2009).  
 
 After microinjection with DNA, the fertilized egg is grown in vitro for about 5 days to 
the blastocyst stage to improve its vigor, then it is implanted into the uterus of a foster animal 
that has been prepared with hormone injections to mimic pregnancy (Figure-2).  If the technique 
works, the injected gene will be incorporated into the genome and passed on to the founder 
animal‟s offspring.  The technique is reliable, but one problem is that the injected DNA can be 
incorporated anywhere in the genome, producing wildly different results among different 
founders even when injected with the same transgene (Walinski, 2004).  So a subsequent 
screening of the transgenics made using this technique is important to map the site of insertion to 
ensure the transgene did not insert into an inactive region of the chromosome, and that no 
essential animal genes have become inactivated. 
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Figure-2:  Diagram of the Egg Microinjection Process for Making a 
Transgenic Animal.  The male pronucleus is shown in blue and the 
female pronucleus in red.  The embryo is held in place with gentle 
suction (right side), and the male pronucleus is injected with DNA (blue 
needle).  The nuclei merge following mitosis (diagram right), and the 
embryo is implanted into the uterus of a recipient (diagram lower).  
(http://www.scq.ubc.ca/studying-gene-function-creating-knockout-mice/) 
 
 
Creating Transgenics Using Embryonic Stem Cells 
 
 The second main technique for creating a transgenic animal is manipulation of embryonic 
stem (ES) cells. In this process, an embryo is created by in vitro fertilization.  The embryo is 
grown about 5 days to the blastocyst stage, and its ES cells are isolated from the inner cell mass.  
The ES cells are then manipulated to take up foreign DNA using microinjection, transfection, or 
viral infection. The manipulated ES cells are then injected back into a blastocyst (Figure-3), and 
the embryo implanted into the uterus of a recipient (Figure-4). 
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Figure-3:  Photograph of ES Cell Microinjection into 
a Mouse Blastocyst.  The mouse blastocyst is being held 
in place by suction with a pipette on the left and on the 
right are the genetically modified ES Stem Cells being 
injected inside (Oregon Health and Science University, 
2009). 
 
 
 
 
 
 
 
 
 
Figure-4:  Diagram of the ES Method for Making a 
Transgenic Animal.  The diagram shows the 
microinjection of manipulated embryonic stem (ES) 
cells (diagram upper right) into a blastocyst (upper 
left).  The reconstituted embryo is then implanted into 
the uterus of a recipient (diagram center) to eventually 
create a transgenic pup (lower right) (Walinski, 2004).   
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The main advantage of the ES technique is it allows the use of the natural biological 
process of homologous recombination to target the foreign gene to a specific site in the host 
chromosome to ensure the transgene is not inserted in an inactive region of the chromosome, and 
to ensure no essential host gene is inadvertently inactivated.  Homologous recombination is a 
natural biological process that takes place during mitosis where two pairs of sister chromatids 
align side by side (Figure-5).  At some points along the aligned chromosomes they connect at a 
point called the chiasma (panel B) and exchange DNA segments (panel C) (Shorn et al., 2003).   
When making a transgenic animal, this naturally occurring recombinant process is used to 
exchange genetic information from the cloning vector we create to the identical region of the 
host genome we wish to target (Davidson College, 2002).  The cloning vector contains the 
foreign transgene plus two regulatory genes to insure proper expression of the gene.  The 
regulatory genes (or their flanking sequences) are also complementary to specific sites in the host 
genome.  After manipulation of the ES cells to insert the vector DNA, the complementary 
sequences in the vector bind to the complementary sites in the host chromosome to pair, insuring 
predictable site integration.     
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Figure-5:  Diagram of Homologous Recombination.  During the 
natural biological process of mitosis, homologous chromosomes pair 
(panel A).  During the pairing, DNA sometimes exchanges between 
complementary regions of chromatid strands (panel B) to create 
chromatin exchange (panel C).  The enzymes that perform this natural 
exchange process can be used to target transgene DNA to specific sites in 
the host animal‟s chromosome.  (http://www.web-
books.com/MoBio/Free/Ch8D1.htm) 
 
 
 Another popular method of integration of transgene DNA into an animal genome uses 
viral delivery.  In nature, viruses efficiently infect their host cells with their own genetic material, 
so viruses engineered to contain a transgene can be an efficient delivery method.   The most 
commonly used viruses used for gene delivery in transgenesis are retroviruses because they 
integrate viral DNA directly into a chromosome (Figure-6).  However, with this technique there 
are safety issues with respect to viral replication.  Although the virus used for gene delivery is 
usually engineered to lack key replicative genes, there is a concern that the engineered viruses 
could recombine with wild type viruses to create an infectious virus.  Retrovirus delivery usually 
yields a 5 to 10% transfection efficiency (Lasic, 1997). 
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Figure 6:  Diagram of Gene Insertion by Retroviruses.  A mature 
retrovirus (diagram upper left) attaches to receptors present on the 
surface of a host cell.  The virus enters the cell (diagram upper center), 
and the capsid disassembles (upper right) exposing the viral genome.  
The RNA genome is converted to DNA by reverse transcriptasae 
(diagram center) and the viral DNA integrates into the host gemome 
(diagram lower center).  This natural infection process has been used to 
deliver foreign DNA into animal genomes for transgenesis (Lund 
University, 2007). 
 
 
 
 
Screening Transgenic Animals 
 
 In order to determine the success of creating a transgenic animal, the DNA of the 
transgenic founder animal or its offspring is tested for the presence of the transgene and its 
expression.  The assays usually used first test for the presence of the transgene in the DNA of the 
host animal.  Usually Southern blots or PCR are used for this purpose.  A Southern blot detects 
specific DNA sequences (i.e. a transgene) in the presence of a complex mixture of DNA (i.e. a 
host animal‟s genomic DNA) (Khalsa, 2000).  The host DNA is broken up with restriction 
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enzymes which cut DNA at certain sequences.  The DNA fragments are then separated by size 
on an agarose gel using an electric current.  DNA is negatively charged so it moves towards the 
anode, the smaller fragments move further.  The DNA is then split into single strands, called 
denaturing, to allow it to hybridize to a probe for the transgene.  The denatured DNA is then 
blotted to a nitrocellulose membrane and treated with UV light linking the DNA to the 
membrane.  For accuracy you can then add nonspecific single stranded DNA to limit the binding 
of our probe to unwanted sequences (pre-hybridization), after which is followed by hybridization 
to the transgene probe.  After hybridization the probe will be visually apparent,  whether by 
radioactive labeling, bioluminescence, or of colorimetric methods (Figure 7). 
 
 
 
 
 
 
 
 
 
 
 
Figure 7:  Southern Blot Analysis.  The dark black bands denote 
specific DNA fragments that have hybridized to the DNA probe 
indicating their presence in the cut DNA fragments present on the gel.  
This technique can be used to determine whether a specific transgene is 
present in a host animal‟s DNA (Wang et al., 2005).   
 
To determine whether a transgene is being expressed into protein in the transgenic 
animal, usually Western blots or ELISAs are used.  These techniques are well suited for 
verifying the presence of a specific protein (i.e. trans-protein) in a complex mixture of proteins 
 13 
(i.e. cellular proteins of the host animal).   In the Western blot (immunoblot), cellular proteins are 
separated by size using SDS-polyacrylamide gel electrophoresis (Khalsa, 2000).  The proteins on 
the gel are then blotted to a nitrocellulose membrane, and the membrane is incubated with a 
primary antibody that specifically attaches to the protein of interest (Figure-8) to confirm 
whether it is present or absent, and if present at which levels (Khalsa, 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8:  Sample Western Blot.  The photo shows the use of three 
different antibodies (first three lanes) to detect three different proteins in 
a mixture of proteins.  This technique can be used to determine whether a 
transgene is correctly expressed (ThermoScientific, 2009). 
 
 
 The second assay commonly used to determine transgene expression is the enzyme-
linked immunosorbent assay (ELISA).   Plastic wells are coated with an antibody to be used to 
capture the protein of interest (i.e. trans-protein) (Figure-9).  The sample is then added (i.e. a 
blood sample from a potential transgenic animal).  If the trans-protein is present in the blood 
sample, it binds to the antibody coating the well.  Unbound proteins are removed by washing, 
then a second antibody is used to detect the presence of the captured transprotein.  The greater 
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the level of attachment of secondary antibody to the well, the greater the presence of transprotein 
in the well, and the stronger the color formation (University of Arizona, 1998). 
 
 
 
 
 
 
 
 
 
Figure 9:  Photograph of an ELISA.  Shown is a 96-well microtiter 
plate treated as described in the text.  The darker the green color, the 
higher the concentration of specific protein in the well.  This technique 
can be used to quantitate the level of transgenic protein present in a 
transgenic animal (University of Arizona, 1998). 
 
 
 Using the techniques described in this chapter, scientists are able to manipulate an 
animal‟s genome to insert a foreign gene and screen whether they were successful in their 
experiment.  Subsequent chapters will focus on the types of animals that have been created, and 
their effects on society. 
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Chapter 2:  Types of Transgenic Animals 
 
Ryan Clinton 
 
 Now that we have discussed the main technology for making and screening transgenic 
animals, we turn our attention to which animals have been produced so far.  The purpose of this 
chapter is to categorize and document the main types of transgenic animals created to date, as a 
basis for discussion in the next chapter as to whether such animals should be made.  There are 
five main categories of transgenic animals, each with a very specific and important use:  disease 
models, transpharmers, xenotransplanters, food sources, and scientific models. 
 
Disease Models 
 This particular branch of transgenics is one of the most medically beneficial branches 
because of the immediate impact they have on our knowledge of human disease initiation and 
cures.  They offer vast numbers of subjects for testing potential medicines for human diseases, 
without the risk of human test subject casualties. These offer hope for people with specific 
diseases which currently have no cure, such as cancer, AIDS, Alzheimer‟s disease, and 
Parkinson‟s disease. 
 
Oncomouse 
 Cancer is an uncontrolled replication of cells in the body.  This disease can be caused by 
damage to DNA, especially tumor suppressor genes that normally work to hinder tumor 
formation, or by activation of oncogenes that lead to unconrolled cell growth. Oncomouse was 
first created at Harvard University by Philip Leder and Timothy Stewart in the mid 1980‟s 
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(Leder and Stewart, 1984). The animal was created by inserting the human oncogene ras into the 
mouse genome, so the mouse showed a predisposition to tumors.  This would allow an 
investigation into tumorigenesis and the screening of potential therapeutics.  In their patent 
application, Leder and Stewart mentioned the potential use of this transgenic as a test to see if a 
specific material is carcinogenic (Leder and Stewart, 1984). Another important potential use of 
these transgenics is the development of anti-cancer or anti-tumor drugs.  Since its creation, 
Oncomouse has been used for many research venues, including adding to our knowledge of 
various chemopreventive agents which prevent uncontrollable cell growth (Alexander, 2000). 
 
AIDS Mouse 
 AIDS is an immunodeficienty disease caused by infection with HIV.  The virus 
predominately infects macrophages and helper T-cells, critical components of the immune 
system.  Unfortunately there currently is no cure for AIDS.  Progress has been hindered due the 
the lack of an affordable animal model other than primates in which to study infection and 
potential cures.  Initially, scientists studied the process of immuno-suppression in the SCID 
(severe combined immunodeficiency disease) mouse which lacks an immune system.  When 
homozygous for this mutation, the animal has diminished B-cell, T-cell, and Natural Killer cell 
populations and functions (Senpuke et al, 2003).    
 But the SCID mouse does not support HIV replication since it lacks appropriate HIV 
receptors and key host proteins required for viral replication, so other transgenic rodents have 
recently been created as HIV models containing these key proteins (Reid et al., 2001; Ambrose, 
2007).  Robert Gallo‟s lab created an HIV rat by inserting the human gene for cyclin-T, a host 
cell protein required for HIV replication (Reid et al., 2001). Other mice have been created that 
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express human CD4 and CCR5 HIV co-receptors required for HIV entry.  Thus research 
scientists now have better models than expensive primates to study this disease (Ambrose, 2007).  
 
Alzheimer’s Mouse 
 Alzheimer‟s disease is caused by the buildup of neurotoxic β-amyloid (a waxy protein 
fragment) in various areas of the brain. The interaction of β-amyloid with receptors on the 
neuronal cell surface causes the hyperphosphorylation of tau protein, which destabilizes 
microtubules to form neurofibrillary tangles, eventually resulting in cell death.  The β-amyloid 
builds up both outside and inside of neurons, when it is outside of the neurons, it eventually 
aggregates to form senile plaques. When it builds up inside a neuron, it typically finds its way 
into the mitochondria, which further disrupts cell function, and can also trigger apoptosis. 
 The first Alzheimer‟s Mouse disease model was created by Prof. Dave Adams and 
colleagues (Games et al., 1995) by inserting the gene for human amyloid precursor protein (APP) 
into mice. The APP inserted was a particular version first identified in a family in Indiana that 
develops an early onset version of the disease (the Indiana mutation).  The human APP protein 
gets cleaved to β-amyloid to initiate the disease.  This mouse line was the first to demonstrate 
that β-amyloid synthesis is necessary and sufficient for initiating Alzheimer‟s disease.   The 
mouse line was subsequently used for screening various therapeutic drugs for blocking β-
amyloid production, and was used by Elan Pharmaceuticals Inc. to test a vaccine for removing 
the toxic β-amyloid from brains to demonstrate its removal was beneficial for brain function 
(Schenk et al., 1999).  The Elan Alzheimer‟s vaccine is currently in phase-III human clinical 
trials. 
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Parkinson’s Fly 
 Parkinson‟s disease (PD) is a neurodegenerative disease caused by the decreased 
production and/or function of the dopamine produced by dopaminergic neurons.  This condition 
eventually leads to muscle tremors, a slowing of body movement, and eventually a cessation of 
movement. Currently, there is no cure, although dopamine analogs have been used to temporarily 
retard symptom progression (Krantz, 2007).   As with AIDS, research progress on PD has been 
hindered by a lack of affordable animal models other than primates.  
 Parkinson‟s fly was created by inserting a mutated gene for human parkin into a fruit fly. 
This causes the fly to demonstrate many of the neurodegenerative symptoms similar to the 
human disease, including the hallmark drop in dopamine.  The flies experience a muscle and 
mesoderm degeneration which results in a diminished flying ablility and grip (Greene et al, 
2003).  In this model, the males are sterile because the parkin gene is inactivated in sperm 
leading to a lack of mitochondrial function. To date, no Parkinson‟s drugs have been developed 
using this particular model, but hopefully will in the future. 
 
Transpharmers 
 Transpharmers are one of the most interesting results yielded by the advent of 
transgenics.  These animals present the possibility of a source of affordable and replenishable 
medicine for those abroad who really need it.  Animals are engineered to produce various 
medicines or drugs in their body.  The animals are usually made to secrete the drug in the blood 
or  milk, allowing easy drug purification, thus transpharmers are essentially bioreactors.  
 Transpharming as a field has come a long way since its original inception.  The original 
transpharmers were mice and other small rodents (Gordon et al, 1987); however, the protein 
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could not be produced in large quantities in small rodents, so scientists eventually began working 
with larger animals such as sheep, goats, and cattle (Houdebine, 1994). Mice were an important 
step in the field of transgenics, mainly because of the rapid rate at which they mature and begin 
to produce milk. 
 A mouse producing human tPA was the first transpharmer ever created (Gordon et al, 
1987).  This protein is an important clot-dissolving drug used to open arteries following heart 
attacks.  Some very important sheep have also been created, such as a sheep producing an anti-
hemophilic clotting factor in its milk (Clark et al, 1989), and a sheep which produces human α-1-
antitrypsin an emphesema drug.  The latter was a very important finding because it proved that 
transpharming could yield a large amount of functional protein (Wright et al, 1991).  
 Transgenic goats were the next step up the ladder of protein production, because they 
produce more milk, but they take slightly longer to produce it. A great example of a 
transpharming goat is the Genzyme Transgenics-Tufts collaboration project in Framingham, 
MA. These two prestigious organizations combined their efforts to create the first transpharming 
goats that produced human antithrombin III, an anti-coagulant (Genzyme Transgenics, 1999).  
 With respect to milk production, the field eventually focused on transgenic cattle.  The 
worlds first transgenic cow (now quite famous) was Herman the bull (Krimpenfort et al., 1991). 
Herman was created in 1990 by the Dutch company Pharming, and was engineered to pass on 
the genes required to create human lactoferrin (Cho, 2002), an antimicrobial protein which, as an 
example, interferes with the gp120 receptor in human cells decreasing the efficiency of HIV 
infection.  Although Herman did not transpharm milk himself, he was a success in that his 
female offspring produced lactoferrin in their milk, but not in high enough quantities to be 
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useful.  This eventually caused Pharming to drop the project, and move on to working on ways to 
improve the yield in cow transpharmers. 
 Scientists continue to try to improve transpharmer technology.  In one study, researchers 
isolated a nearly immortal cell line (KIM-2) from the mammary glands of a pregnant mouse, and 
used the cells to insert a gene encoding a protein of interest, then inserted the transformed cells 
back into the mammary gland of the animal (Gordon et al, 2000). This process produces an 
animal that is transgenic only in the mammary gland, and is more efficient than creating an entire 
transgenic animal from a blastocyst.  Although the technique can be applied to any of the 
transpharming mammals, it would not be inheritable. 
 
Xenotransplanters 
 This specific branch of transgenics is of special interest to doctors and people around the 
world because if successful, organ donors will no longer be a rare commodity.  The current well 
documented organ shortage causes countless lives lost, and has created an illegal market for 
human organs (Organ Transplants, 2008). With xenotransplanters, this market will no longer be 
viable since the transgenic organs produced by these animals will be much less expensive. Most 
animal organs are viewed a foreign inside humans, and immunorejected due to the presence of 
specific sugar residues on their surface.  Xenotransplanters are engineered to not produce these 
glycoprotein markers on their organs which allow their organs to be used for donors no matter 
what antibodies the host has (Lai et al., 2002). The animals lack glycosyl transferase enzymes 
used to add the sugars to the cell surface.  Pigs are chosen for these experiments because their 
physiology closely matches that of humans.  Because of the sheer value of the organs contained 
in one of these xenotransplanting pigs, they can be worth more than a million dollars. Such 
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animals can be used to donate organs such as livers, kidneys, lungs, etc., and can also be used to 
donate tissue such as beta-islet cells for diabetic patients.  UPMC, a medical company, is looking 
into commercializing these pigs soon, and distributing them to the 11 national organ storage 
locations so their organs can be readily available and the transplant wait lists can be cleared once 
and for all (Fabregas, 2006). 
 
Food Sources 
 This branch is of transgenics is bred to provide food.  The animals have had a growth 
hormone added to make them grow faster and larger with less food intake.   
 
Superpig 
 Superpig is the common name for a group of pigs transgenically modified to include 
either human growth hormone (hGH) or bovine growth hormone (bGH) (Miller et al., 1989).  
The pigs expressed a higher production of their respective growth hormone with age (Miller et 
al, 1989).  Ovine growth hormone (oGH) has also been tested.  In all examples, the promoter for 
these genes is normally off until switched on by a high zinc diet.  Although the Superpig, also 
known as the Beltsville pig, was a major leap towards improving a major world food source, it 
came with drawbacks. The altered pigs suffered from a variety of ailments including early onset 
arthritis, multiple organ failure, and sight issues caused by bugged out eyes.  After the realization 
that these pigs would be plagued by health issues, a voluntary moratorium was placed on the 
transgenic addition of growth hormone to any mammalian host (Taylor, 1998). 
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Superfish 
 With respect to food sources, scientists have had better luck adding growth hormone 
genes to fish.  Scientists have managed to create several transgenic fish which mature faster, and 
consume less food, which are very important for aquaculture.  Contrary to popular belief, these 
transgenic superfish do not become monstrously larger than their wild-type counterparts, but 
grow to slightly larger than usual, but tend to reach that size more rapidly, and mature faster 
overall.  Also, they don‟t need to eat as much food as their wild-type counterparts because their 
bodies metabolize food 10-30% more efficiently (Devlin et al, 2001).  Optimists say this food is 
only a few years away from FDA approval for consumption. 
 One concern is that these engineered fish will escape their hatcheries, and outcompete the 
natural fish, so the geneticists who created them engineered them to be sterile. This is done with 
a moderate success rate by forcing the animal to be triploid (three sets of chromosomes) (Aken, 
2000).  This triploidy results in males or females with the genotype (XXY or XXX), and they 
lack genitalia.  Satisfying environmentalists concerns will be important before such fish can be 
raised in large quantities. 
 
Biological Models 
 Biological model is the name applied to any animal generated to increase our knowledge 
of the function of a specific protein.  When a new protein is first discovered, key experiments 
often involve over-expressing it, or alternatively knocking it out, to determine the effects on the 
animal. 
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ANDi the Monkey 
 ANDi the monkey has a very specific name for a very specific reason: the name is iDNA 
backwards, standing for “inserted DNA”.  This little rhesus monkey is the proof of concept for 
the possibility of eventually creating transgenic humans. ANDi is also the basis for a line of 
research involving the future creation of primate disease models, which scientists hope will allow 
them to more closely model (and create treatments for) human diseases. ANDi showed that 
primates can be the recipients of transgenic genes, but in this specific case he does not mimic a 
human disease or transpharm a drug.  He carries a gene encoding green fluorescent protein 
(GFP), as a marker protein to prove the technology works. Unfortunately the gene was not 
expressed (Begley, 2001), but the fact that the transfection occurred was all that was necessary.  
Transgenic primates will be the subject of much controversy in the future, and will be discussed 
in Chapter-3. 
 
Smart Mouse 
 According to Hebb‟s Rule, when two neurons fire together, they form stronger synaptic 
bridges which allow them to subsequently fire more effectively.  One way synaptic bridges can 
be made stronger is if they express the NR2b subunit of the glutamate receptor, as do most 
neurons in a newly forming brain.  Scientists hypothesized that transgenic mice over-expressing 
NR2b might learn faster (Tang, 1999; Harmon, 1999). This process of  facilitating bridging 
between multiple neurons is also called long term potentiation (LTP). Mice with an upregulated 
or overexpressed NR2b gene have an increase in LTP, which means that they learn and 
remember how to complete a maze test faster than a normal mouse.  
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 This research on the glutamate receptor also led to the creation of a new disease model, 
when scientists realized that mice over-expressing the NR1 subunit of the glutamate receptor 
show schizophrenic behaviors. This shows that a possible gene therapy treatment (lowering NR1 
expression) might be used to treat certain types of schizophrenia, and similar diseases (Bliss, 
1999).  
 
Supermouse 
 Supermouse is the generic name for any sort of mouse which has been altered to include 
a foreign growth hormone in with its natural genome. There have been several versions: a 
version with a rat growth hormone (rGH) (Palmiter et al., 1982), and a version with hGH 
(Palmiter et al., 1983).  These „super‟ animals are given growth hormone attached to a 
metallothionein promoter which is triggered by the presence of either cadmium or zinc in the 
animal‟s diet.  This process results in an animal with a much greater physical prowess than their 
wild-type counterparts, and that can undergo a large amount of physical activity over a long 
period of time, has a much faster metabolism (so much so that it requires >50% more food to 
live), and has no obvious quality of life sacrifices (Connor, 2007). This line of experimentation is 
important for helping demonstrate the function of the various types of growth hormones, and 
used the same promoter as the Superpig experiments. The difference is that the mouse is much 
more able to accept the higher metabolism and body mass alterations than the pig was.  
 
Youth Mouse 
 Youth mouse is the term applied to a mouse which has been altered to include an over-
expressed mouse urokinase-type plasminogen activator (MUPA) which has the interesting effect 
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of making the host mouse live about 20% longer, and grow to a smaller size (about 20% lighter 
and 6% shorter) (Miskin and Masos, 1997).  It seems that the attenuation of the aging process in 
these mice is caused by the lack of excess calories metabolized by the mouse. When compared to 
a mouse that simply had a diet with fewer calories, very similar longevity was found (Miskin et 
al., 2004).  
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Chapter 3:  The Ethics and Morals 
of Transgenics 
 
Ryan Clinton 
 
 The ethical and moral boundaries pushed by modern biotechnology is a hotly debated 
topic because of the many strong viewpoints on the topic. The Merriam-Webster English 
dictionary defines ethics as “the discipline dealing with what is good and bad, and with moral 
duty and obligation”; using that definition as my guide, I will discuss transgenic viewpoints from 
various organizations and people worldwide to document what many people feel about this field.  
Based on this research, I will then form my own opinion by first describing clear “good” and 
clear “bad” cases, and finally moving into the middle ground where the distinction is not as clear.  
 
Various Organizational Views of Transgenics 
 Many organizations tend to have very strong opinions on the topic of transgenic animals, 
but their views vary a great amount based on the tenants of the organization. Some object to the 
idea based on the possibility that the world‟s biomass might shift following the release of 
transgenic animals into the environment, while others debate the ethics behind causing possible 
harm to the animals.  Others debate the religious implications of tampering with the genomes 
with humans and lesser species. 
 Greenpeace disagrees with the idea of creating a genetically modified organism because 
of the implications it has towards the natural biodiversity of the Earth.  They worry that one day, 
genetically modified organisms (GMOs) will replace the natural animals of the earth, so in 1992, 
 30 
Greenpeace initiated its “Cartagena protocol”, an agreement signed by over 150 countries 
(Greenpeace, 2005).  This protocol imposed restrictions on the shipment and distribution of 
GMOs, and greatly impeded the release of any GMO into the environment. It requires shipments 
of GMOs to contain documentation stating the exact destination and intent of the cargo, as well 
as precise handling protocols to ensure that the contents are not accidentally released into the 
wild (USDA FAS, 2003).  The main and very obvious argument by Greenpeace is that these 
organisms are not natural, and therefore should not taint the world with their unnatural genomes 
and artificial advantages. 
 There is also an interesting paper written by the Interchurch Bioethics Council, which 
debates the “ethical, spiritual, and cultural” aspects of this science (Jarvis et al, 2006).  One of 
this group‟s main issues is mankind‟s „duty to be responsible for, and steward, our fellow 
creatures. Their analysis at one point focuses on New Zealand‟s native Mauri people‟s beliefs 
that the mixing of genes is offensive and insensitive.  This is thought to be an important concept 
due to New Zealand‟s highly intermingled multicultural core.  Also, one important fact noted by 
the council, not previously considered by the author of this chapter, is the consumption of an 
animal containing a human gene could be seen as cannibalism. The Mauri tribe also has concerns 
about the consumption of transgenic animals because of previous issues they had with the 
neurological disorder Kuru, caused by the ingestion of neurological tissue containing prions.  
However, the ingesion of tissues contaminated with disease causing prions is very different than 
for example ingesting a transgenic salmon containing the human gene for growth hormone (not 
prions).  I found this paper to be an eye-opening one which made me think more about different 
core belief systems, not just religious ones, and to broaden my perspective of what types of 
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circumstances might influence various countries to disagree with genetically engineered 
organisms in general, especially genetically engineered food sources (Jarvis et al, 2006). 
 A paper published on bioethics by a group of Seventh Day Adventists was very 
interesting because they actually accept the idea of genetic engineering and genetic testing, but 
with certain stipulations outlined by passages in the bible (Loma Linda University, 1997).  With 
respect to genetic manipulation, they believe it should be limited only to critical health  related 
enhancements, and approve nothing else (Loma Linda University, 1997).  Based on this stance, 
transgenic animals such as Alzheimer‟s mouse, Oncomouse, Transpharmers, and 
Xenotransplanters would be allowed, but not Superfood.   
 In their Professional Ethics Report, the American Association for the Advancement of 
Sciences (AAAS) discusses many factors on the general American view on GMOs and genetic 
research.  They logically address many of the issues that several of the aforementioned 
organizations brought up as key issues with the field of transgenics. They begin by addressing 
various fears about genetically modified crops. The commercially available crops have 
alterations giving them a resistance to a certain factor which kills many plants. They are typically 
either an herbicide resistance factor or a mild insecticide, and neither of these are harmful to 
humans. They also mention how these can have detrimental results to non-human members of 
the environment such as the insecticide being poisonous to non-targeted insects, and the 
possibility of creating resistant strains of insects (Siang, 2000). 
 This author found all of these various commentaries very informative about the scope and 
breadth of opinions on the topic of transgenic animals. While some concerns were fairly 
expected and could be addressed by a small about of research into the subject, other concerns 
were encountered that I found unexpected.  The Mauri tribe‟s concerns about the possibility of 
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prion development and symbolic cannibalism weren‟t something this author expected to see 
while researching this. It certainly brings a new viewpoint and set of concerns into plain sight.  
 
Non-Ethically Justified Examples 
 One way to help determine whether a particular transgenic experiment is ethical is to 
consider the benefit of that particular experiment to society weighed against any detriments to 
the animal.  We now turn our attention to various transgenic examples, some are clearly ethical 
in this author‟s views, others are clearly non ethical, and others are less clear. 
 In this author‟s views, there are only a few clear-cut examples of transgenics which fall 
into a negative ethical area.  One of the best examples in this category is Superpig.  As discussed 
in Chapter-2, this animal was engineered to overexpress either human or bovine growth hormone 
(Pursel et al., 1990) to allow it to grow larger with less fat, on less food intake.  Unfortunately, 
the animal eventually experienced severe health issues, including lethargy, lameness, gastric 
ulcers, a lack of libido, and several other issues (Pursel et al., 1990; Rollin, 1996).  So these pigs 
are in constant pain and they do not reproduce normally.  The construction of these animals 
reminds us that it is impossible to predict the exact outcome of inserting a particular foreign gene 
into animals, so in some cases the only way to find out is to make the change and observe the 
effects.  Because of this unpredictability, we must try to reduce the numbers of animals 
experimented on until the effects are known for a given gene, and in the case where an animal is 
observed to suffer, to reduce its suffering in any way possible including pain killers or euthanasia 
(Rollin, 2003). 
 In this author‟s opinion, the transgenic Superpig is the only example of a non-ethically 
justified transgenic animal; all other types have strong benefits to society and should be allowed. 
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Ethically Justified Transgenic Examples 
 Based on the criteria discussed above, a positive transgenic example would be a case in 
which the animal provides a strong medical benefit to society, and does not appear to suffer in 
any way.  Based on the author‟s research, one example in this category are Transpharmers that 
are engineered to produce life saving drugs in their milk, but who appear to suffer no ill health 
effects.  Based on the research performed so far in this type of animal, they over-express a 
protein of value in their milk, but this protein has no physiological effect systemically on the 
animal.  This situation would be very different than expressing the protein in the animal‟s blood 
(Society Religion and Technology Project, 2001).  Moreover, to obtain the medical benefit, the 
animals do not need to be sacrificed, they only need to be milked, so the medical benefit to 
society does not result in the death of the animal. 
 Another good example of an ethically justified transgenic experiment in this author‟s 
views is the Alzheimer‟s mouse.  This animal is a disease model which presents the symptoms of 
Alzheimer‟s Disease (AD) by over expressing amyloid precursor protein (APP) which allows the 
buildup in the brain of amyloid plaques consisting of toxic β-amyloid (Aβ ) which mimics 
human AD (Games et al., 1995).  With respect to medical benefits to society, the construction of 
a disease model for this disease aids our understanding of the initiation of Alzheimer‟s, and 
serves as a model for testing new therapeutic drugs.  Even though the mice show the physical 
and mental signs of Alzheimer‟s disease, and learn slower on a learning test, they do not present 
with any observable detrimental changes, and do not have an altered quality of life (Hsiao et al., 
1996).  
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Ethically Unclear Transgenic Examples 
 Because of the complicated nature of some of these transgenic animals, and their 
complex intended uses, a few experiments fall into an ethically gray area in this author‟s views.  
I think the best example of this ethically gray area is the xenotransplanter pig, a pig whose cells 
have been genetically altered to not express specific glycoprotein residues on the surface that are 
viewed as foreign by the human immune system.  This general type of animal is also called a 
knockout transgenic because its genetic alteration deletes the expression of one of its own genes 
instead of expressing a foreign human gene.  The potential medical benefit of working with 
transplant animals, especially pigs due to their compatible physiology to humans, is immense for 
patients awaiting transplant organs.  
 Organ donations currently occur post-mortem, but the donor must be histocompatible 
with the recipient, which does not occur very often, leaving an organ shortage (Correa, 2001). 
The number of people awaiting transplants has reached record high levels.  For example, in the 
United Kingdom patients awaiting organ transplantation reached an all time high of 7234 
(Dobson, 2007).  In the United States, there are about 100,000 people on the Organ 
transplantation waiting list, while only 9000 transplantations actually occurred between January 
and April of 2009 (U.S. Transplant Data, 2009).  Thus, many feel that we are morally bound to 
try and find another way to procure these organs to save lives. 
 The ethical dilemma with xenotransplanters is the animal must be sacrificed to obtain its 
organs to save a human life.  Many organizations such as the Animal Aid Youth Group feel that 
this type of activity is heinous, and possibly harmful to the world by increasing the chances of a 
porcine virus entering humans to cause a pandemic (Animal Aid Youth Group, 2006).  However,  
arguments in favor of xenotransplantation come from the International Xenotransplantation 
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Association, in fact it is one of the rare groups this author encountered which provided a positive 
outlook on the field of xenotransplantation (O‟Connell, 2003). The entire purpose of this 
organization is to promote xenotransplantation as a valid, ethically acceptable, practice for 
saving human lives. They aim to do this by advocating strong legislative oversight of the entire 
process to ensure no unethical activities occur, and making the technology and its virtues known.  
 In this author‟s view, these pigs are close to the borderline of „ethically justified‟/‟not 
ethically justified experiments, but one factor rises above the others, the chance of saving human 
lives.  Although I share the viewpoint of some groups, that animal lives are not worthless, I do 
not share the viewpoint that they are equivalent.  And the animal suffering is not chronic as with 
Superpig, it occurs only at time of euthanasia.  Therefore as long as the organs will function 
properly in the human body, and will not pass on non-human pathogens, I am all for 
xenotransplantation.  
 Oncomouse is another ethically questionable creature because we have given it one of the 
worst illnesses known to man.  Oncomouse has been altered to make it more susceptible to 
developing the genetic mutations which result in cancerous growth. As discussed in chapter 2, 
these animals are often created by inserting a human oncogene into the mouse‟s genome which 
gives it a predisposition to develop tumors (Leder and Stewart, 1984).  In this author‟s opinion, 
Oncomouse is the closest grey example to being non-justified because it was given a terrible 
disease, but the redeeming factor here is that they have been used to further our knowledge of 
cancer to save human lives (Alexander, 2000).  This author believes that Oncomouse is an 
ethically justified transgenic experiment because of its potential for curing cancer, as long as the 
suffering of the animals is closely monitored and moderated, there should be no reason to 
ethically argue against this type of transgenic animal. 
 36 
 
Chapter-3  Conclusion 
 The author of this chapter feels that transgenic experiments cannot all be lumped together 
into one group with one clear ethical outcome, but each experiment must be individually 
analyzed and judged.  Some types appear clearly ethical, other types are clearly unethical, and 
others require deep thought and consideration.  Personally, I think that Transpharmers are clearly 
ethical, as they provide strong medical benefit with no apparent animal suffering or sacrifice.  
This type of transgenic is possibly one of the most useful and beneficial for all of mankind.  It 
has the potential to create a renewable source of drugs, while being relatively easy to maintain.  
Alzheimer‟s mouse is also in this category, providing a critical model for testing drugs to block 
this devastating disease, while causing no observable suffering to the animal.   Xeno-
transplantation in my opinion is the second most important transgenic category next to 
transpharming.  When xenotransplantation is perfected, and the organs are immune-response-free 
and pathogen-free, it will save the lives of thousands of people annually awaiting organ 
transplants or dying from transplant rejection. 
 The most unethical and immoral practice in transgenics to date was the Beltsville pig 
(Superpig) which led to massive animal suffering and behavioral changes, while providing no 
strong medical benefit to society.  To this day there is a voluntary moratorium instituted by 
scientists prohibiting mammalian growth hormone experimentation.  Non-mammalian growth 
hormone experimentation on the other hand (Superfish), has great potential to help feed the 
world by creating a source of food whose population is ready for consumption much quicker and 
on less food than its wild-type counterpart.  Though some are worried about these animals 
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escaping into the wild, they have been engineered to be incapable of growing genitalia by an 
imposed triploidy, so this is not a problem. 
 In this author‟s view, any transgenic research which is beneficial to society and does not 
cause outrageous or unmediated animal suffering, is not only ethically justified, but is almost 
imnmoral to not do such experiments.  It is important to do all that is possible to save human life, 
and as long as no undue animal pain is caused, the world will be improved. 
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Chapter 4:  Transgenic Legalities 
 
Gregory Richmond 
 
 
 As is typical for any controversial technology, laws have been enacted to control the 
construction of transgenic animals.  From a legal stand point, one of the most controversial 
topics surrounding transgenic animals is whether an individual or company can patent life, and if 
so to what extent.  Scientists want to patent their transgenic animals to claim their research as 
their own in the eyes of the law, and to perhaps make a profit to continue performing research, 
while activists don‟t want them to be able to do this arguing you can‟t put a price-tag on life.  
The purpose of this chapter is to discuss some of the early court cases involved with patenting 
life as an example of the impact of a new technology on society. 
 
The First Patents on Life 
 The first patent of a living organism was granted in 1930 and was entitled the Plant 
Patent Act, which covered newly developed asexually reproducing plants.  However, until 1980, 
no patents had been allowed on animals or microbes.  The first patent awarded for a microbe was 
presented in 1980-1983 to Dr. Ananda M. Chakrabarty who developed a bacterium able to break 
down crude oil into shorter chain molecules (Diamond vs. Chakrabarty, 1980).  This bacterium is 
not naturally occurring, so it initially appeared to satisfy the three main requirements of a patent:  
it was useful, new, and non obvious (Ladas.com, 2003).  But because the case involved a living 
microbe the case was actually quite prolonged with appeals.  
 Dr. Chakrabarty‟s patent claim was in three parts: 1) the process of producing the oil 
digesting bacteria, 2) the system for delivering the bacteria to the oil, and 3) the bacteria 
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themselves.  The US Court of Customs and Patent Appeals initially allowed the first two tenants, 
but denied the third tenant, arguing that the bacterium created by Dr. Chakrabarty was not a 
“product of nature” but was changed and manipulated by his own hands, and therefore the 
modified bacterium is not patentable under the U.S. patent law, which states: 
“Whoever invents or discovers any new and useful process, 
machine, manufacture, or composition of matter, or any new and 
useful improvement thereof, may obtain a patent therefore, subject 
to the conditions and requirements of this title.” 
 
 However, The Court of Customs and Patent Appeals in 1983 reversed the initial rejection 
allowing the third tenant, arguing the engineered bacterium is a new “manufacture” and  
“composition of matter” as outlined in the Patent Law of 1793.  The Patent and Trademark 
Office in a now famous statement said: 
“The Patent and Trademark Office now considers nonnaturally 
occurring non-human multicellular organisms, including animals, 
to be patentable subject matter. The Board’s decision does not 
affect the principle and practice that products found in nature will 
not be considered to be patentable subject matter. An article of 
manufacture or composition of matter occurring in nature will not 
be considered patentable unless given a new form, quality, 
properties, or combination not present in the original article…” 
(Edwards, 2001). 
 
 This 1980-1983 case set a landmark precedence that multicellular organisms including 
animals can be patented, and acted as a framework for one of the most famous legal cases of all 
time, Harvard‟s Oncomouse. 
 
Oncomouse Courtcase in the United States 
 The first complex living organism to be patented in any country was Harvard and 
Dupont‟s Oncomouse.  Philip Leder of Harvard produced this transgenic cancer prone mouse in 
work funded by Dupont, by incorporating the human oncogene myc into the mouse‟s genome, 
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which triggers tumor growth.  As discussed in Chapter-2, Oncomouse provides us with the 
ability to research cancer origins and cures in a convenient lab model system, but the Oncomouse 
courtcase raised serious questions of whether animals should be patentable, and how should the 
morals of animal suffering be addressed in relation to allowing the patent.  After several appeals, 
the patent was eventually granted in 1988 to Dupont and Harvard College for a process for 
preparing transgenic animals, and for cloning oncogenes.  To address moral concerns that 
humans cannot be patented, the transgenic patent excluded humans and any modifications of the 
human genome (WIPO, 2006). 
 
Oncomouse in Europe  
 In Europe, oncomouse had to answer to two articles of The European Patent Office‟s 
(EPO) guidelines.  In Europe, patents are not awarded if  “the publication or exploitation of 
which would be contrary to ordre public or morality.”  Also European patents at that time 
excluded “animal varieties or biological processes for the production of...animals” (WIPO, 
2006).   In 1989, Oncomouse was initially denied in Europe because the patent law clearly stated 
that no animal variety may be patented.  But this was appealed under the premise that 
oncomouse is not an animal variety (new species), but is a new engineered animal.  The appeal 
was awarded in 1992 (Sharples and Curley, 2009).   
 After the 1992 initial patent award, the next problem for the scientists was the opposition 
from third parties who claimed that the mouse did not fall under the “morality” ordre public 
clause outlined in European patent laws.  To answer this morality question, the European 
oncomouse case addressed whether the transgenic animal‟s suffering outweighs the medical 
benefits to society.  The EPO eventually found that the medical benefit of increasing our 
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understanding of cancer initiation, and screening potential cancer drugs, outweighed the mouse‟s 
suffering, so the European patent was finally awarded in 2004 (WIPO, 2006).    
 
Oncomouse in Canada 
 Although the Oncomouse patent was eventually awarded in the US and Europe, Canada 
took a different approach.  The Canadian and American patent systems are very similar in terms 
of what can be patented, but have one very significant difference.  In America anything made by 
humans is patentable, including a mouse.  In Canada, microorganisms can be patented, but 
anything considered a complex organism cannot (Bird and MacOdrum, 2008).  Following 
Canadian patent law, Canada ruled that the mouse itself was not patentable, but the processes 
used to create oncomouse were (WIPO, 2006).  Canada‟s laws state that a patent must be a 
“manufacture or composition of matter within the meaning of invention” (WIPO, 2006).   From 
the Oncomouse findings, “manufacture” was defined as a non-living process, and “composition 
of matter” was defined as a mixture of substances combined by a person.  The single cell mouse 
egg injected with the myc oncogene was patentable as a new composition of matter, but the 
multicellular mouse itself did not fall under Canadian patent law (WIPO, 2006). 
 In 2002, Harvard scientists appealed this decision as they had in Europe, and it was 
initially ruled that the altering of genetic material was a form of “composition of matter”, and 
that Oncomouse fell within the patent law, but this apellate ruling sparked outrage with the 
animal rights activists and religious groups who argued that patenting animals would prevent the 
distribution of research materials in other fields of research, drug and treatment discovery 
(Check, 2002).  The opponents also argued that the moral downfalls of allowing an animal to be 
patented outweigh any possible research benefits.  So the Canadian government, after receiving 
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numerous letters from activists and religious groups in Canada, appealed the case for a second 
time, and the outcome was to overturn the patent as no longer valid in Canada.  The Canadian 
Supreme court justified their decision by stating that life is not just a “composition of matter” 
(Mitchell and Somerville, 2002).   To this date, Canada remains the only developed nation to 
reject the Oncomouse patent. 
 
Recent FDA Regulations 
 With respect to patenting animals in the US, recent guidelines were released in January 
2009 by the Food and Drug Administration for governing the use of genetically modified 
animals.  These new guidelines consider the recombinant DNA in transgenic animals as a drug, 
giving the FDA the ability to regulate such patents.  The FDA will thus investigate the safety and 
environmental impacts of transgenic animals.   
 In the original drafted guidelines released in September 2008, scientists and citizens were 
concerned with the lack of transparency in the patenting process.  So the new guidelines, to 
provide more insight into the patenting process, mandate the holding of public advisory 
committee meetings before the FDA will approve anything.  Citizens still have some concern 
over the transparency though, because the information released in the public advisory meetings 
will be restricted.  The public also concerned over the FDA‟s ability to evaluate risks of the 
transgenic animals, and the lack of labeling requirements on transgenic animal products (Ledford 
2009).   Preventing the consumer from knowing details doesn‟t reduce any of their concerns. 
 
 
Chapter-4 Conclusion 
 Transgenic animals, like other products, are an industry, which provide jobs and 
competition.  In the case of transgenic animals, competition between scientists leads to faster and 
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better “products” ranging from disease cures to bigger and healthier food.  The more scientists 
learn, the more benefits society gets.  New technology can also lead to more investments, 
expanding research opportunities, and new jobs in the industry.   
 The new FDA regulations put in place are there to aid in the question morality.  It isn‟t 
easy to obtain a patent for a transgenic animal.  Oncomouse is a prime example of this; it still is 
not patented in Canada, and it took over a decade to be patented in Europe.  The recent FDA 
regulations, while under criticism, are a step in right direction for the United States, as they 
attempt to bring openness to the process for public view.  The patent office is there to decide 
what is patentable according to the law, and the author of this chapter agrees that another 
institution needs to weigh the morality. 
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PROJECT CONCLUSIONS 
 
 
 
 The authors of this IQP believe that further development should be done with transgenic 
animals in the categories as superfish, Alhezimers mouse, and transpharmers.  All of these 
examples provide strong benefits to society with no observable animal suffering.   
 Other cases are not so clear cut when some animal suffering is observed.  In the case of 
superpig, the scientific community proved it can regulate itself with their voluntary moratorium 
on human growth hormone insertion into mammalian hosts, and the authors agree such 
experiments should be banned.  With respect to xenotransplanters, the authors believe that with 
their strong medical benefit to society (transplants in a world of severely limited donors), this 
area of should be developed since the animals could be sacrificed humanely to obtain the organs, 
unlike with superpig where the pain was chronic.  With respect to oncomouse, the authors feel 
that, as was stated at the conclusion of the European oncomouse case, the benefits to society 
outweigh any suffering by the mouse.  And with the use of early euthenasia and painkillers, the 
pain could be minimized while still achieving the benefits.  The documented court rulings that 
allow scientists to patent their transgenic animals represent a great stepping stone for scientists to 
protect and further their research.  Although the authors agree with the patenting of transgenic 
animals, we also believe that as the industry grows, more regulations will be needed to control it. 
 
